Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

United Kingdom: These 3 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License.

Preferred citation:
Friedman, Yali, "United Kingdom: These 3 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral

These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in the United Kingdom

Last updated: March 22, 2026

A review of scheduled patent expirations for branded drugs in the UK for the second quarter of 2026 indicates multiple patent lapses that could open market segments to generic competition.

What Are the Key Patent Expiry Dates for Q2 2026?

Drug Name	Patent Expiration Date	Manufacturer	Therapeutic Area	Notes
Humira (adalimumab)	May 2026	AbbVie	Rheumatology, immunology	First patent expiry; biosimilars under regulatory review
Eliquis (apixaban)	June 2026	Pfizer/Bristol Myers Squibb	Cardiology, anticoagulation	Patent expiry processes ongoing; biosimilars anticipated
Revlimid (lenalidomide)	June 2026	Celgene (BMS)	Oncology	Patent expiration expected to impact multiple markets
Novorapid (insulin aspart)	July 2026*	Novo Nordisk	Diabetes	Patent expiry may influence insulin biosimilar entry

*Note: Some patent dates are subject to extensions or legal challenges, potentially altering the actual expiry window.

Patent and Market Context

The UK's patent system follows the European Patent Office (EPO) framework, with patent terms generally lasting 20 years from filing. Patent expirations often stabilize market entry timelines for generics and biosimilars, contingent on regulatory approval and market dynamics.

For biologics like Humira and Revlimid, patent expiration opens opportunities amid biosimilar development. The UK Medicines and Healthcare products Regulatory Agency (MHRA) plays a critical role in biosimilar approvals, which can influence the actual timing of generic market entry.

Impact on Market Dynamics

Aspect	Effect of Patent Expiry
Generic Competition	Increased entry risks for branded products
Pricing Pressure	Likely decline in branded drug prices
Market Share	Shift towards biosimilars and generics
Prescriber Preference	Transition contingent on biosimilar trust

The timeline aligns with broader European patent expirations, but specifics depend on legal proceedings and local patent rights. Manufacturers might seek extensions or patent challenges, which could delay generic entry.

Regulatory and Legal Factors

The UK has provisions for patent extensions including supplementary protection certificates (SPCs), which can extend patent protection up to five years beyond standard terms. Patent litigation can also influence expiration dates.

Biosimilar approvals depend on demonstrating equivalence, which can take two to four years from application to market. The UK’s regulatory pathway involves comprehensive safety and efficacy evaluations, critical for biosimilar market success.

Summary of Key Dates and Implications

Humira: May 2026, major biologic being challenged but likely to face biosimilar entry within 1–2 years post-expiry.
Eliquis: June 2026, anticipated market shift towards generic anticoagulants.
Revlimid: June 2026, significant for oncology segment, with biosimilar penetration expected soon after.
Novorapid: July 2026, insulin biosimilars poised to compete, following typical approval timelines.

Strategic Considerations

Investors and pharmaceutical companies should monitor ongoing patent litigation, regulatory approvals, and biosimilar development timelines to refine market entry and competitiveness strategies.

Key Takeaways

Multiple high-value biologics with patent expirations in Q2 2026 in the UK.
Expirations create opportunities for biosimilar and generic entrants, influencing prices and market shares.
Patent extensions or legal challenges can alter the typical timing of market entry.
Biosimilar approval timelines generally span two to four years, affecting the post-expiry market landscape.
Stakeholders should closely track regulatory developments and patent disputes affecting key drugs.

FAQs

1. Which drugs are most likely to see biosimilar entry post-Q2 2026?
Humira and Revlimid are major biologics with patent expirations in 2026, with biosimilar entry expected within one to two years after expiry.

2. How do patent extensions affect the expiration date?
Patent extensions, including SPCs, can delay expiry by up to five years, influencing the timing of generic entry.

3. What role does the UK’s regulatory authority play?
The MHRA approves biosimilars based on safety and efficacy, influencing actual market entry timelines.

4. Are patent litigations common around expiry periods?
Yes. Patent disputes aim to extend exclusivity or challenge the validity of patents, potentially delaying generic entry.

5. How significant is the impact on drug prices?
Patent expirations generally reduce prices as competition increases; biosimilars typically further lower costs.

References

[1] Expiring Drugs Patent Database. (n.d.). Accessed 2023.
[2] UK Medicines and Healthcare products Regulatory Agency. (2023). Biosimilar guidance.
[3] European Patent Office. (2022). Patent Term Extensions.
[4] FDA. (2022). Biosimilar Product Development and Approval.

More… ↓

⤷ Start Trial

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 23, 2026
Generic Entry Controlled by: United Kingdom Patent 612,540

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch?

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2026
Generic Entry Controlled by: United Kingdom Patent 613,692

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

When can BYFAVO (remimazolam besylate) generic drug versions launch?

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 10, 2026
Generic Entry Controlled by: United Kingdom Patent 613,694

When can QVAR REDIHALER (beclomethasone dipropionate) generic drug versions launch?

Generic name: beclomethasone dipropionate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 11, 2027
Generic Entry Controlled by: United Kingdom Patent 706,999

QVAR REDIHALER is a drug marketed by Norton Waterford. There are seventeen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries. There has been litigation on patents covering QVAR REDIHALER

See drug price trends for QVAR REDIHALER.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the beclomethasone dipropionate profile page.

Last updated: December 28, 2025

Summary

The UK pharmaceutical market, comprising both branded and generic sectors, presents significant opportunities amid evolving regulatory landscapes and healthcare reforms. This report evaluates supply chain dynamics, market size, key players, regulatory frameworks, and prospective risks affecting stakeholders. It delineates strategic opportunities for growth, highlights regulatory challenges, and offers actionable insights for pharmaceutical companies, investors, and policymakers.

Market Overview

Size and Growth Dynamics

The UK pharmaceutical market was valued at approximately £16.2 billion in 2022, with projected compound annual growth rate (CAGR) of 3.2% over the next five years (IQVIA, 2022).
The branded segment accounts for roughly 65% of market value, while the generic segment contributes approximately 30-35%.
Increasing emphasis on cost containment and NHS formulary policies accelerates demand for generics.

Market Composition

Segment	Market Share (2022)	Key Drivers	Notable Trends
Branded Drugs	65%	Innovation, patent protection, specialty medicines	Growth of biotechnology products, high-cost therapies
Generic Drugs	30-35%	Cost pressures, patent expirations	Rapid uptake, bioequivalence, regulatory easing

Major Players

Branded Sector: Pfizer, Novartis, Roche, AstraZeneca
Generic Sector: Teva Pharmaceuticals, Sandoz (Novartis), Mylan (now part of Viatris), Accord Healthcare, Aurobindo

Regulatory Framework in the UK

Overview

Post-Brexit, the UK Drug Regulatory Agency (UK Medicines and Healthcare products Regulatory Agency, MHRA)国t continues to oversee drug approval, safety, and market authorization, aligning with European standards but with distinct policies to foster innovation and streamline approvals.

Key Regulations and Policies

Regulation/Policy	Description	Impact on Market
Human Medicines Regulations 2012	Implemented UK-specific rules post-Brexit, aligned with EU directives	Licensing, compliance
The UK National Medicines Policy	Emphasizes access, affordability, and quality	Pricing, reimbursement considerations
Health and Social Care Act 2012	Framework for NHS procurement and formulary management	Reimbursement landscape
Medicines and Medical Devices Act 2021	Enhances oversight of medical devices and medicines' safety and efficacy	Market surveillance, post-market monitoring

Regulatory Pathways

Pathway	Description	Applicability	Lead Time	Notes
Full Marketing Authorization	Standard approval process	New molecular entities, biologics	210 days	Similar to EMA processes
Conditional Approval	Accelerated pathway for unmet needs	Rare diseases, urgent needs	Variable	Facilitates faster access
Generic Drug Approval	Based on bioequivalence	Established formulations	Approx. 6 months	Simplified pathway

Opportunities in the UK Pharmaceutical Market

1. Expansion of Generic Medicine Portfolio

Patent expirations of blockbuster drugs (e.g., Lipitor, Plavix) open pathways for generic entry.
The NHS’s push for cost savings magnifies opportunities for bioequivalent, cost-effective alternatives.

2. Biosimilar Development

UK’s focus on biosimilars offers growth avenues, especially in oncology and autoimmune diseases.
Regulatory pathways for biosimilars are well-established, supporting accelerated market entry.

3. Innovation in Specialty and Rare Disease Products

Rising demand for personalized medicine and advanced therapies.
MHRA’s streamlined approval mechanisms for orphan and rare disease drugs.

4. Digital Transformation and Manufacturing

Adoption of digital health tools for drug development and monitoring.
Opportunities in advanced manufacturing, including continuous manufacturing and sustainability initiatives.

5. Strategic Collaborations and Licensing

Access to the NHS’s procurement framework.
Public-private partnerships for drug research and distribution.

Regulatory Challenges and Risks

1. Navigating Post-Brexit Regulatory Divergence

Potential for divergence from EMA standards requires vigilance.
Increased compliance costs and delays in approval processes for imported or co-developed medicines.

2. Pricing and Reimbursement Pressures

The NHS’s Cost-Effectiveness Analysis (CEA) and NICE’s (National Institute for Health and Care Excellence) stringent evaluation criteria limit profit margins.
Price controls and tendering processes impact margins.

3. Market Access Delays and Complexity

Lengthy and complex approval processes for innovative products.
Variations in regional NHS procurement policies may cause inconsistencies.

4. Patent and Intellectual Property Risks

Increased competition from generics and biosimilars post-patent expiry.
Patent litigation and uncertainties affecting innovation incentives.

5. Supply Chain and Regulatory Compliance

Brexit-induced supply chain disruptions.
Ensuring compliance with UK-specific pharmacovigilance and post-market surveillance.

Comparative Analysis: UK vs. European Union & US

Aspect	UK	EU	US
Regulatory Agency	MHRA	EMA	FDA
Market Access Speed	Faster (due to streamlined processes)	Similar, but longer due to multiple countries	Longer, more complex approval processes
Price Regulation	NHS pricing negotiations, NICE evaluations	Price negotiation varies; generally less government-led	Market-driven pricing, higher reimbursement margins
Biosimilar Adoption	Leading in Europe, focused on biosimilars	Active development, growing uptake	Rapid adoption, high competition
Patent Term & Data Exclusivity	8+2+1 years (UK), aligned with UK law	Up to 10 years, plus supplementary protection certificates	Up to 12 years data exclusivity

Strategic Recommendations

Priority	Action Items	Rationale
Engage with MHRA early	Expand Regulatory Knowledge, expedite approvals	Minimize delays, ensure compliance
Invest in biosimilars and generics	Strengthen R&D, optimize manufacturing	Capitalize on patent cliffs, NHS cost constraints
Monitor Brexit-related regulatory changes	Adjust compliance strategies	Maintain market access, prevent delays
Develop partnerships with NHS	Leverage procurement frameworks	Increase market penetration
Embrace digital health tech	Enhance data, compliance, and supply chain	Improve efficiency, reduce regulatory hurdles

Key Takeaways

The UK market presents lucrative opportunities for generics, biosimilars, and specialty medicines driven by patent expiries, cost containment, and innovation.
Post-Brexit regulatory environment necessitates vigilance, agility, and proactive compliance strategies.
Price pressures from NHS and NICE policies continuously shape product profitability.
Strategic collaborations, digital transformation, and early engagement with MHRA can mitigate regulatory risks.
Market entry success hinges on aligning product development with evolving UK-specific policies, safety standards, and procurement frameworks.

FAQs

Q1: How does Brexit affect drug approval times in the UK?
Brexit has led to the UK establishing its own regulatory pathway through MHRA, which, in some cases, results in faster approval times than the EMA, especially with expedited routes for certain therapies. However, divergence from EMA can also introduce complexities for companies needing dual approvals.

Q2: What are the key regulatory requirements for biosimilars in the UK?
Biosimilars must demonstrate biosimilarity in terms of efficacy, safety, and quality, following MHRA guidance similar to EMA standards. Data packages are typically less extensive than novel biologics but require equivalence studies and robust quality assurance.

Q3: How does the NHS impact drug pricing and market access?
NHS, through NICE evaluations and procurement frameworks, prioritizes cost-effectiveness, often negotiating for lower prices and preferential inclusion. This severely influences margins and incentives, favoring generic and biosimilar entry.

Q4: What are the intellectual property challenges post-patent expiry?
Patent expiry opens the market for generics, but companies face risks of patent litigation and market saturation. Post-expiry, competition intensifies, putting pricing pressure on branded products.

Q5: What opportunities exist for biotechnological innovations in the UK?
The UK actively promotes biotech R&D, with favorable regulatory pathways for advanced therapies, gene therapies, and personalized medicine. This creates substantial avenues for innovative product pipelines.

References

IQVIA, "UK Pharma Market Overview," 2022.
MHRA, "Guidelines for Biosimilars," 2021.
UK Human Medicines Regulations, 2012.
NICE, "Guidance on Cost-Effectiveness and Market Access," 2022.
Department of Health and Social Care, "UK Pharmaceutical Policy Framework," 2021.

What Are the Key Patent Expiry Dates for Q2 2026?

Patent and Market Context

Impact on Market Dynamics

Regulatory and Legal Factors

Summary of Key Dates and Implications

Strategic Considerations

Key Takeaways

FAQs

Summary

Market Overview

Size and Growth Dynamics

Market Composition

Major Players

Regulatory Framework in the UK

Overview

Key Regulations and Policies

Regulatory Pathways

Opportunities in the UK Pharmaceutical Market

1. Expansion of Generic Medicine Portfolio

2. Biosimilar Development

3. Innovation in Specialty and Rare Disease Products

4. Digital Transformation and Manufacturing

5. Strategic Collaborations and Licensing

Regulatory Challenges and Risks

1. Navigating Post-Brexit Regulatory Divergence

2. Pricing and Reimbursement Pressures

3. Market Access Delays and Complexity

4. Patent and Intellectual Property Risks

5. Supply Chain and Regulatory Compliance

Comparative Analysis: UK vs. European Union & US

Strategic Recommendations

Key Takeaways

FAQs

References

Make Better Decisions: Try a trial or see plans & pricing